- Research areas
- Oncology
Oncology
These AIHTA assessments evaluate the efficacy and safety of (new) cancer drugs to facilitate evidence-based decision-making.
Research projects
Lung cancer screening in risk groups Systematic review(s) of effectiveness and utility (part 1) Costs and budgetary consequences (part 2)
Project leaders: Claudia Wild (part 1), Ingrid Zechmeister-Koss (part 2)
Project team:
- Thomas Semlitsch (IAVEM) & EUnetHTA partners (IQWIG, potentially others) (part 1)
- Christan Böhler, Sarah Wolf (part 2)
Duration: May 2020 – November 2020
Language: English with German summary
Publications:
HTA Project report No. 132a: http://eprints.aihta.at/1282/ (part 1)
HTA Projektbericht Nro 132b: https://eprints.aihta.at/1283 (part 2)
Stereotactic radiotherapy (Cyberknife®), proton beam therapy and irreversible (electroporation Nanoknife®) for localised prostate cancer (PCa): a systematic review
Project leaders: Claudia Wild
Project team: Louise Schmidt, Pia Lohr
Suggested by: Main Association of the Austrian Social Security Institutions
Duration: February 2018 – June 2018
Language: German (with English summary)
Publication: LBI-HTA Project report No. 107: https://eprints.aihta.at/1165
Health Services Research (HSR) in oncology in a selected indication: Cancer therapies for lung patients
Project team: Nicole Grössmann-Waniek
Support in data evaluation and processing: DexHelpp
Duration: October 2018 – December 2019
Health Services Research (HSR) in oncology: end-of-life therapies
Project leaders: Martin Robausch
Project team: Martin Robausch
Supported by DexHelpp (data-requirements and -acquisition), Nicole Grössmann
Duration: January 2018 – March 2020
Publication: LBI-HTA Project report No. 127: http://eprints.aihta.at/1233
Health Services Research (HSR) in oncology: Analysis of Austrian data
Project leaders: Nicole Grössmann-Waniek
Project team: Nicole Grössmann-Waniek
Supported by DexHelpp (data-requirements and -acquisition), Martin Robausch
Duration: January 2018 – December 2019
Publication:
Clinical benefit of oncology drugs – Contrasting the evidence of clinically relevant endpoints three years after EMA approval
Project leaders: Nicole Grössmann-Waniek
Project team: Nicole Grössmann-Waniek
Duration: December 2017 – March 2020
Publications:
Positron emission tomography/ Computer tomography (PET/ CT): need-assessment for planning
Project leaders: Claudia Wild
Project team: Claudia Wild
Duration: September 2014 - December 2014
Publication: LBI-HTA Project report No. 77: https://eprints.aihta.at/1045
Horizon scanning in oncology
Project leaders: Nicole Grössmann-Waniek, Sarah Wolf
Project team: Sarah Wolf, Eleen Rothschedl, Nicole Grössmann-Waniek
Duration: since Oktober 2009
Appraisal of the quality and accuracy of written consumer health information for patients with chronic myeloid leukaemia on treatment-regimens with dasatinib, nilotinib or imatinib
Project leaders: Claudia Wild
Project team: Katharina Hintringer, Jone Gerdvilate
Duration: April 2011 - February 2012
Quality of care in oncology and its measurement
Project leaders: Claudia Wild
Duration: February - October 2011
